Stock·NYSE·Financial Services
JPMorgan Chase & Co. (JPM)
- Market cap
- $902.16B
- P/E
- 13.91
- Dividend yield
- 1.81%
- Street target
- $373.50median of 25 analysts
- 52-week range
- $279.10 $366.50
The short version
Where JPM stands today, in four lines, and what CleaRank Financial AI makes of it.
JPM at a glance
JPMorgan Chase & Co. (JPM): Buy, 64/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($322.37 and $348.12).
- Earnings JPM beat estimates in 6 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $164.5M and made no open-market purchases over the last 18 months.
- Valuation P/E of 13.9 against 16.5 for the Financial Services sector: broadly in line with peers (-16%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates JPMorgan Chase & Co. (JPM) Buy, with a model score of 64/100.
The trend lifts the score most: the price is 5.38% above its 200-day average, and the 50-day average is 7.99% above the 200-day. Momentum holds it back most: the MACD line is negative. The 50-day average stands at $348.12 and the 200-day at $322.37. Over the past year the price rose 13.79%.
Only on CleaRank
Figures we compute ourselves from JPM's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $339.72 is 2.4% below the 50-day simple moving average of $348.12.Price above its 200-day average ›
The price is 5.4% above the 200-day simple moving average of $322.37.50-day average above the 200-day ›
The 50-day average ($348.12) is 8.0% above the 200-day average ($322.37), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 69% of its 52-week range, between $279.10 and $366.50.
JPM share price
Pick a period: each tab shows how far JPM has moved over it, to the last close.
Today's trading
Where JPM sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 13.91 is 15.7% below the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 4.67 is 22.9% above the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $64.5B on revenue of $190.7B, a net margin of 33.8%.Beat estimates in most recent reports ›
JPM beat the EPS estimate in 6 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.81%, or $6.15 a share a year.
Key statistics
The headline figures for JPM.
As of October 17, 2026, JPM trades at $339.72, with a market value of $902.16B, a P/E ratio of 13.91 and a dividend yield of 1.81%.
What the numbers say
CleaRank Financial AI's reading of JPM's valuation, growth and risks.
Set against its sector, JPM's trailing P/E of 13.91 is 15.7% under the Financial Services median of 16.5, and the peer comparison on this page labels that valuation broadly in line with peers. On sales, the P/S of 4.67 sits 22.9% over the sector median of 3.8. Put in size terms, the company's market value is $902.2B.
Over the latest year revenue expanded 10.20%, a pace that trails the 11.7% sector median for Financial Services by 1.5 percentage points. Margins are strong, with a net margin of 34.59% and an operating margin of 42.58%. Return on equity is 18.01%, above the sector median of 13.8%. Debt-to-equity sits at 0.04, and the trailing dividend yield is 1.81%, or $6.15 a share each year.
JPM's latest report, released on October 13, 2026, showed EPS of $5.75. Analysts had pencilled in $5.94, so the company missed the estimate by 3.20%. Despite that shortfall, the stock climbed 1.16% in the next session.
JPM has topped the EPS estimate in 6 of its last 8 reports, but the share price still dropped in the next session after 3 of those 6 beats. Looking ahead, analysts expect this fiscal year's average EPS to reach $24.11, a rise of 22.2%, followed by $25.09 next year, which is growth of 4.1%.
On a typical day the price of JPM shifts by 1.04%, the 30-day standard deviation of its daily returns. Over the last 18 months, insider sales totalled $164.5M with no open-market purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
JPM against the Financial Services sector
How JPM compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-16% difference), suggesting fair market pricing relative to industry standards.
Return vs XLF: Since May 6, 2025, JPM has gained 36.3% against a gain of 12.9% for XLF.
Performance against XLF
JPM and the Financial Services sector fund over the same days.
Revenue and earnings
How much JPM sells, and how much of it becomes profit.
Revenue growth: Revenue grew 7.3% in FY2025 to $182B, from $169B a year earlier.
Profit margin: The net margin was 31.4% in FY2025, down from 34.5% the year before.
Profitable: JPM earned $57.0B in FY2025.
Earnings reality check
Did JPM beat what analysts expected, and how did the stock react?
Earnings record: JPM beat the analyst estimate in 6 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 13, 2026after close | $5.94 | $5.75 | -3.20% | +1.16% | - |
| Jul 14, 2026after close | $5.80 | $6.14 | +5.86% | +1.17% | +0.68% |
| Apr 14, 2026after close | $5.51 | $5.94 | +7.80% | -1.67% | +0.60% |
| Jan 13, 2026after close | $4.82 | $4.63 | -3.94% | -0.97% | -2.85% |
| Oct 14, 2025after close | $4.87 | $5.07 | +4.11% | +1.20% | -1.65% |
| Jul 15, 2025after close | $4.48 | $4.96 | +10.71% | -0.25% | +1.70% |
| Apr 11, 2025after close | $4.64 | $5.07 | +9.27% | -0.63% | -3.05% |
| Jan 15, 2025after close | $4.04 | $4.81 | +19.06% | +0.76% | +5.39% |
As of October 17, 2026, JPM has beaten the analyst EPS estimate in 6 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on October 13, 2026, came in 3.20% below the estimate and the stock moved +1.16% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 51.0, in neutral territory.RSI above 50 ›
An RSI of 51.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of JPM
The score, the reasoning behind it, and what could move the price next.
JPM is caught between its two moving averages. At $339.72, the stock sits 5.38% above its 200-day average of $322.37 but 2.41% below its 50-day average of $348.12. That leaves the 50-day average 7.99% above the 200-day, a spread that would shrink if the price keeps trading beneath the shorter average. Within its 52-week range, running from $279.10 up to $366.50, the price stands at 69%.
A recent pullback sits inside a stronger longer record: the price fell 2.64% over the past month, fell 0.40% over the past three months and rose 13.79% over the past year. On momentum, the 14-day RSI reads 51.0, in the neutral zone, with the MACD line negative.
Earnings miss ›
The October 13, 2026 report missed the EPS estimate by 3.20%, and the share price rose 1.16% in the first session after it.
Source: Earnings report, October 13, 2026
Rating reaffirmed ›
TD Cowen kept its Hold rating on October 8, 2026.
Source: Analyst action, TD Cowen, October 8, 2026
- Keep an eye on the two closest levels: the 50-day SMA at $348.12 sits above the price, while the 20-day EMA at $337.28 sits below it.
- The 14-day RSI reads 51.0, in the neutral zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- Following the October 13, 2026 report, the share price gained 1.16% in the first session. Over the last 8 reports, JPM has beaten estimates in 6.
JPM's trend signals point in different directions: the price is above its 200-day average at $322.37 yet below its 50-day average at $348.12. Closing above the 50-day would bring both signals up, while closing below the 200-day would bring both down. Until then, the price is wedged between the 20-day EMA ($337.28) below and the 50-day SMA ($348.12) above.
A 14-day RSI of 51.0 places the stock in neutral territory, inside the 40 to 60 band.
Technical indicators
Momentum and trend for JPM, from its daily closes.
As of October 17, 2026, with JPM at $339.72, its 14-day RSI is 51.0 (neutral territory), its 50-day simple moving average is $348.12 and its 200-day is $322.37.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What JPM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, JPM's 1-year correlation of daily returns is +0.61 with S&P 500 (SPY), +0.47 with Nasdaq 100 (QQQ), +0.23 with Bitcoin (BTC) and +0.12 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
13 of 25 analysts rate it a buy or strong buy, 12 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $373.50 is 9.9% above the price.More buy ratings than three months ago ›
13 of 25 rate it a buy now, against 12 of 23 three months ago.
JPM Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | TD Cowen | Reinstates | Hold |
| Oct 5, 2026 | UBS | Maintains | Buy |
| Sep 28, 2026 | HSBC | Maintains | Hold |
| Aug 14, 2026 | Wells Fargo | Maintains | Overweight |
| Aug 3, 2026 | UBS | Maintains | Buy |
| Jul 20, 2026 | Citigroup | Maintains | Neutral |
As of October 17, 2026, 25 Wall Street analysts cover JPM: 13 rate it a buy or strong buy, 12 a hold and 0 a sell or strong sell. Their 12-month price targets range from $305.00 to $420.00, with a median of $373.50, 9.9% above the price of $339.72.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
JPM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from JPM's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much JPM tends to move, against the market and on its own.
The long record
JPM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.04% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 38.5%, from January 2020 to March 2020, regained by January 2021.Most 1-year holds ended higher ›
74% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $65,492, against $42,055 in the S&P 500 (SPY).
JPM Drawdowns & Recovery
As of October 17, 2026, JPM's worst peak-to-trough fall over the last 10 years with dividends reinvested was -38.5% (January 2020 to March 2020); it regained that peak by January 2021, 10 months after the low, and 74% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into JPM in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: JPM beat the S&P 500 over this period: $65,492 against $42,055.
A $10,000 investment in JPM in October 2016 would be worth about $65,492 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to JPM, and which have not.
Strongest month, November: an average of +7.67%, up in 7 of 10 years.
Weakest month, March: an average of -4.32%, up in 1 of 10 years.
This month, October: has averaged +3.37%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, JPM's strongest calendar month has been November (average +7.67%, up in 7 of 10 years) and its weakest March (average -4.32%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in JPM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in JPM today could grow to about $25,489 by 2036 in the base case, with a 90th-percentile outcome near $77,285 and a 10th-percentile outcome around $8,406. The simulation models price only; at today's 1.81% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
JPM Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $494 for JPM by 2030 in the base case, from $340 today (1.5x over 4 years). The 10th-percentile path ends near $245. These are outcomes of a Monte Carlo simulation run on JPM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $263 | $373 | $530 | |
| 2028 | $249 | $410 | $673 | |
| 2029 | $245 | $450 | $826 | |
| 2030 | $245 | $494 | $996 | |
| 2031 | $248 | $542 | $1,188 |
Method: a lognormal simulation of JPM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
JPM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought JPM shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, JPM insiders reported 51 open-market sales worth $164.5M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Robin Leopold
Officer
|
Sell | 2.5K | $882.0K |
| Aug 11, 2026 | Robin Leopold
Officer
|
Sell | 2.5K | $903.5K |
| Jul 27, 2026 | Stacey R. Friedman
General Counsel
|
Grant | 166 | - |
| Jul 24, 2026 | Douglas B Petno
Officer
|
Grant | 864 | - |
| Jun 30, 2026 | Stephen B Burke
Director
|
Grant | 171 | $56.3K |
| Jun 30, 2026 | Mellody L Hobson
Director
|
Grant | 137 | $45.0K |
| Jun 30, 2026 | Phebe N Novakovic
Director
|
Grant | 122 | $40.0K |
| Jun 30, 2026 | Virginia M Rometty
Director
|
Grant | 122 | $40.0K |
| Jun 22, 2026 | Stacey R. Friedman
General Counsel
|
Sell | 5.5K | $1.8M |
| May 20, 2026 | Stacey R. Friedman
General Counsel
|
Sell | 5.5K | $1.6M |
| May 15, 2026 | Mary E. Erdoes
Officer
|
Sell | 6.6K | $2.0M |
| May 15, 2026 | Marianne Lake
Officer
|
Sell | 6.4K | $1.9M |
| May 15, 2026 | Douglas B Petno
Officer
|
Sell | 5.7K | $1.7M |
| May 15, 2026 | Lori A Beer
Chief Technology Officer
|
Sell | 3.2K | $949.7K |
| May 14, 2026 | Douglas B Petno
Officer
|
Grant | 135.0K | - |
| May 5, 2026 | Jennifer A Piepszak
Chief Operating Officer
|
Sell | 4.9K | $1.5M |
| May 5, 2026 | Ashley Bacon
Officer
|
Sell | 4.1K | $1.3M |
| May 5, 2026 | Jeremy Barnum
Chief Financial Officer
|
Sell | 3.0K | $935.0K |
| Apr 15, 2026 | James Dimon
Chief Executive Officer
|
Sell | 130.5K | $40.0M |
| Apr 15, 2026 | Mary E. Erdoes
Officer
|
Sell | 12.3K | $3.8M |
| Apr 15, 2026 | Jennifer A Piepszak
Chief Operating Officer
|
Sell | 9.1K | $2.8M |
| Apr 15, 2026 | Ashley Bacon
Officer
|
Sell | 7.6K | $2.3M |
| Apr 15, 2026 | Marianne Lake
Officer
|
Sell | 6.4K | $2.0M |
| Apr 15, 2026 | Douglas B Petno
Officer
|
Sell | 5.7K | $1.7M |
| Apr 15, 2026 | Jeremy Barnum
Chief Financial Officer
|
Sell | 5.6K | $1.7M |
| Apr 15, 2026 | Lori A Beer
Chief Technology Officer
|
Sell | 3.2K | $970.7K |
| Mar 31, 2026 | Stephen B Burke
Director
|
Grant | 191 | $56.3K |
| Mar 31, 2026 | Mellody L Hobson
Director
|
Grant | 152 | $45.0K |
| Mar 31, 2026 | Phebe N Novakovic
Director
|
Grant | 135 | $40.0K |
| Mar 31, 2026 | Virginia M Rometty
Director
|
Grant | 135 | $40.0K |
| Mar 25, 2026 | Ashley Bacon
Officer
|
Grant | 47.2K | - |
| Mar 25, 2026 | Jeremy Barnum
Chief Financial Officer
|
Grant | 38.6K | - |
| Mar 25, 2026 | Lori A Beer
Chief Technology Officer
|
Grant | 28.3K | - |
| Mar 25, 2026 | James Dimon
Chief Executive Officer
|
Grant | 320.5K | - |
| Mar 25, 2026 | Mary E. Erdoes
Officer
|
Grant | 85.0K | - |
| Mar 25, 2026 | Stacey R. Friedman
General Counsel
|
Grant | 48.9K | - |
| Mar 25, 2026 | Marianne Lake
Officer
|
Grant | 57.5K | - |
| Mar 25, 2026 | Robin Leopold
Officer
|
Grant | 24.9K | - |
| Mar 25, 2026 | Douglas B Petno
Officer
|
Grant | 50.6K | - |
| Mar 25, 2026 | Jennifer A Piepszak
Chief Operating Officer
|
Grant | 57.5K | - |
| Mar 25, 2026 | Troy L Rohrbaugh
Officer
|
Grant | 73.0K | - |
| Mar 23, 2026 | Robin Leopold
Officer
|
Sell | 433 | $127.8K |
| Feb 19, 2026 | James Dimon
Chief Executive Officer
|
Sell | 69.5K | $21.4M |
| Feb 19, 2026 | Troy L Rohrbaugh
Officer
|
Sell | 50.0K | $15.4M |
| Feb 19, 2026 | Robin Leopold
Officer
|
Sell | 432 | $132.7K |
| Feb 17, 2026 | Mary E. Erdoes
Officer
|
Sell | 5.7K | $1.8M |
| Feb 17, 2026 | Marianne Lake
Officer
|
Sell | 3.9K | $1.2M |
| Feb 17, 2026 | Douglas B Petno
Officer
|
Sell | 3.5K | $1.1M |
| Feb 17, 2026 | Stacey R. Friedman
General Counsel
|
Sell | 3.4K | $1.0M |
| Feb 17, 2026 | Jeremy Barnum
Chief Financial Officer
|
Sell | 2.9K | $886.2K |
| Feb 17, 2026 | Lori A Beer
Chief Technology Officer
|
Sell | 2.0K | $627.2K |
| Feb 3, 2026 | Robin Leopold
Officer
|
Grant | 132 | - |
| Jan 21, 2026 | Douglas B Petno
Officer
|
Grant | 811 | - |
| Jan 20, 2026 | Linda B. Bammann
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Alicia S Boler-Davis
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Michele G Buck
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Stephen B Burke
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | James Dimon
Chief Executive Officer
|
Grant | 90.0K | - |
| Jan 20, 2026 | Alex Gorsky
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Mellody L Hobson
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Phebe N Novakovic
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Virginia M Rometty
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Brad D Smith
Director
|
Grant | 913 | $280.0K |
| Jan 20, 2026 | Mark A Weinberger
Director
|
Grant | 913 | $280.0K |
| Jan 16, 2026 | Jennifer A Piepszak
Chief Operating Officer
|
Sell | 8.6K | $2.7M |
| Jan 16, 2026 | Ashley Bacon
Officer
|
Sell | 7.4K | $2.3M |
| Jan 16, 2026 | Mary E. Erdoes
Officer
|
Sell | 5.7K | $1.8M |
| Jan 16, 2026 | Marianne Lake
Chief Executive Officer
|
Sell | 3.9K | $1.2M |
| Jan 16, 2026 | Douglas B Petno
Officer
|
Sell | 3.5K | $1.1M |
| Jan 16, 2026 | Stacey R. Friedman
General Counsel
|
Sell | 3.4K | $1.1M |
| Jan 16, 2026 | Jeremy Barnum
Chief Financial Officer
|
Sell | 2.9K | $904.9K |
| Jan 16, 2026 | Lori A Beer
Chief Technology Officer
|
Sell | 2.0K | $640.3K |
| Jan 13, 2026 | Ashley Bacon
Officer
|
Grant | 28.9K | - |
| Jan 13, 2026 | Jeremy Barnum
Chief Financial Officer
|
Grant | 24.9K | - |
| Jan 13, 2026 | Lori A Beer
Chief Technology Officer
|
Grant | 17.2K | - |
| Jan 13, 2026 | Mary E. Erdoes
Officer
|
Grant | 50.1K | - |
| Jan 13, 2026 | Stacey R. Friedman
General Counsel
|
Grant | 29.4K | - |
| Jan 13, 2026 | Elena A Korablina
Officer
|
Grant | 14.7K | - |
| Jan 13, 2026 | Marianne Lake
Chief Executive Officer
|
Grant | 33.9K | - |
| Jan 13, 2026 | Robin Leopold
Officer
|
Grant | 14.7K | - |
| Jan 13, 2026 | Douglas B Petno
Chief Executive Officer
|
Grant | 30.0K | - |
| Jan 13, 2026 | Jennifer A Piepszak
Chief Operating Officer
|
Grant | 33.9K | - |
| Jan 13, 2026 | Troy L Rohrbaugh
Officer
|
Grant | 42.8K | - |
| Dec 31, 2025 | Stephen B Burke
Director
|
Grant | 174 | $56.3K |
| Dec 31, 2025 | Mellody L Hobson
Director
|
Grant | 139 | $45.0K |
| Dec 31, 2025 | Phebe N Novakovic
Director
|
Grant | 116 | $37.5K |
| Dec 31, 2025 | Virginia M Rometty
Director
|
Grant | 112 | $36.3K |
| Nov 12, 2025 | Troy L Rohrbaugh
Officer
|
Grant | 9.5K | - |
| Nov 7, 2025 | Robin Leopold
Officer
|
Sell | 966 | $301.3K |
| Nov 5, 2025 | Mary E. Erdoes
Officer
|
Grant | 6.5K | - |
| Nov 4, 2025 | Douglas B Petno
Chief Executive Officer
|
Grant | 809 | - |
| Oct 24, 2025 | Elena A Korablina
Officer
|
Grant | 1.7K | - |
| Sep 30, 2025 | Stephen B Burke
Director
|
Grant | 178 | $56.3K |
| Sep 30, 2025 | Mellody L Hobson
Director
|
Grant | 134 | $42.5K |
| Sep 30, 2025 | Phebe N Novakovic
Director
|
Grant | 118 | $37.5K |
| Sep 30, 2025 | Virginia M Rometty
Director
|
Grant | 110 | $35.0K |
| Sep 2, 2025 | Linda B. Bammann
Director
|
Sell | 9.5K | $2.8M |
| Jul 25, 2025 | Douglas B Petno
Officer
|
Grant | 1.7K | - |
| Jun 30, 2025 | Stephen B Burke
Director
|
Grant | 194 | $56.3K |
| Jun 30, 2025 | Mellody L Hobson
Director
|
Grant | 155 | $45.0K |
| Jun 30, 2025 | Phebe N Novakovic
Director
|
Grant | 129 | $37.5K |
| Jun 30, 2025 | Virginia M Rometty
Director
|
Grant | 120 | $35.0K |
| Jun 12, 2025 | Ashley Bacon
Officer
|
Sell | 5.2K | $1.4M |
| Jun 5, 2025 | Jennifer A Piepszak
Chief Operating Officer
|
Sell | 6.1K | $1.6M |
| May 20, 2025 | Stacey R. Friedman
General Counsel
|
Sell | 9.4K | $2.5M |
| May 16, 2025 | Marianne Lake
Officer
|
Sell | 12.3K | $3.3M |
| May 16, 2025 | Lori A Beer
Chief Technology Officer
|
Sell | 5.9K | $1.6M |
| May 15, 2025 | Douglas B Petno
Officer
|
Sell | 10.1K | $2.7M |
| May 14, 2025 | James Dimon
Chief Executive Officer
|
Grant | 37.8K | - |
| May 13, 2025 | Mary E. Erdoes
Officer
|
Sell | 14.1K | $3.7M |
| May 13, 2025 | Ashley Bacon
Officer
|
Sell | 5.2K | $1.4M |
| May 12, 2025 | Troy L Rohrbaugh
Officer
|
Sell | 12.5K | $3.3M |
| May 6, 2025 | Jeremy Barnum
Chief Financial Officer
|
Sell | 40.0K | $10.0M |
| May 6, 2025 | Linda B. Bammann
Director
|
Sell | 9.5K | $2.4M |
| May 6, 2025 | Jennifer A Piepszak
Chief Operating Officer
|
Sell | 6.1K | $1.5M |
| May 5, 2025 | Linda B. Bammann
Director
|
Grant | 500 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.